Garcia Manero Manuel, Ceamanos Montanes Carolina, Campo Ainhoa, Peru Gema
Objective: To evaluate the effect of the combination of inositolic derivatives and lipid mediators on the metabolic and inflammatory profile of women with polycystic ovary syndrome.
Material and methods: Experimental, prospective and longitudinal study carried out in patients diagnosed with polycystic ovary syndrome (Rotterdam criteria) without treatment or previous dietary intervention. The following nutritional preparations were administered orally daily: Group A: 300mg D-chiro-inositol, 1099mg myo- inositol + 30mg lipinova Group B: 4000 mg of myo-inositol + 30 mg of lipinova The metabolic profile is compared before and after 4 weeks of treatment in each patient, determining the insulin levels and the HOMA index. The inflammatory profile was analyzed by determining the levels of IL-6 before and after treatment.
Results: 41 patients with polycystic ovary syndrome subdivided into 20 from group A and 21 from group B were studied. Insulin levels before and after treatment was 17.9 ± 9.3 SD and 10 ± 4.09 SD, respectively, with statistically significant differences. The HOMA index pre-treatment was 4.1 ± 2.1 SD and 2.1 ± 1.1 SD post-treatment, with significant differences the level of IL-6 was pretreatment was 3.8 ± 1.5 Sd of 2.1 ± 1.09 post treatment with significant differences.
Conclusion: The results of the study show the positive effect of the combined administration of inositolic derivatives and pro-resolution lipid mediators on the metabolic, clinical and inflammatory profile of patients with polycystic ovary syndrome.
इस लेख का हिस्सा
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu 